Annals of Tropical Medicine and Public Health
Home About us Ahead Of Print Instructions Submission Subscribe Advertise Contact e-Alerts Editorial Board Login 
Users Online:3189
  Print this page  Email this page Small font sizeDefault font sizeIncrease font size
 


 
Table of Contents   
LETTER TO THE EDITOR  
Year : 2016  |  Volume : 9  |  Issue : 3  |  Page : 197-198
Indinavir: Chemoinformatics prediction for hepatitis C virus inhibitor property


1 Sanitation 1 Medical Academic Center, Bangkok, Thailand
2 Hainan Medical University, China

Click here for correspondence address and email

Date of Web Publication3-May-2016
 

How to cite this article:
Joob B, Wiwanitkit V. Indinavir: Chemoinformatics prediction for hepatitis C virus inhibitor property. Ann Trop Med Public Health 2016;9:197-8

How to cite this URL:
Joob B, Wiwanitkit V. Indinavir: Chemoinformatics prediction for hepatitis C virus inhibitor property. Ann Trop Med Public Health [serial online] 2016 [cited 2019 Dec 13];9:197-8. Available from: http://www.atmph.org/text.asp?2016/9/3/197/181652
Dear Sir,

The human immunodeficiency virus (HIV) infection is a public health problem worldwide. The use of antiretroviral therapy is the standard management of HIV infection. There are many new anti-HIV drugs, and indinavir is one of those drugs.[1] An interesting concern in using anti-HIV drugs is the effect on other concurrent infection, especially for hepatitis C virus (HCV). In a recent report, the change of anti-HIV regimen is proposed to cause clearance of HCV.[2] Here, the authors use standard biochemoinformatics technique, namely, “General Unrestricted Structure-Activity Relationships – GUSAR” for assessment of the inhibitor effect of indinavir on HCV. This technique is used in some previous publications.[3] According to the prediction modeling, indinavir can have the inhibiting effect on HCV without genotoxicity inductor property. Indeed, the management of concurrent HIV and HCV infection requires targeting on both viruses. Matthews and Dore noted that “new therapies, including HCV protease and polymerase inhibitors, are in development and may widen therapeutic options for HIV–HCV-coinfected individuals.”[4] Nevertheless, if a single antiviral drug can be helpful for managing both diseases, it will be favorable. Based on the present informatics study, indinavir might be helpful as mentioned. However, this needs further clinical study for verification.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
   References Top

1.
Lacy MK, Abriola KP. Indinavir: A pharmacologic and clinical review of a new HIV protease inhibitor. Conn Med 1996;60:723-7.  Back to cited text no. 1
    
2.
Endo T, Fujimoto K, Nishio M, Yamamoto S, Obara M, Sato N, et al. Case report: Clearance of hepatitis C virus after changing the HAART regimen in a patient infected with hepatitis C virus and the human immunodeficiency virus. J Med Virol 2009;81:979-82.  Back to cited text no. 2
    
3.
Masand VH, Mahajan DT, Patil KN, Hadda TB, Youssoufi MH, Jawarkar RD, et al. Optimization of antimalarial activity of synthetic prodiginines: QSAR, GUSAR, and CoMFA analyses. Chem Biol Drug Des 2013;81:527-36.  Back to cited text no. 3
    
4.
Matthews GV, Dore GJ. HIV and hepatitis C coinfection. J Gastroenterol Hepatol 2008;23:1000-8.  Back to cited text no. 4
    

Top
Correspondence Address:
Beuy Joob
Sanitation 1 Medical Academic Center, Bangkok
Thailand
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1755-6783.181652

Rights and Permissions




 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Email Alert *
    Add to My List *


    References

 Article Access Statistics
    Viewed978    
    Printed16    
    Emailed0    
    PDF Downloaded30    
    Comments [Add]    

Recommend this journal